Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

20 luglio 2026 aggiornato da: TScan Therapeutics, Inc.

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a multicenter, genetically-randomized, controlled, Phase 3 study designed to evaluate the efficacy and safety of TSC-101 in adult participants with AML or MDS undergoing allogeneic peripheral blood stem cell transplantation following reduced-intensity conditioning (RIC). TSC-101 is a donor-derived, genetically engineered T-cell therapy designed to express a therapeutic T-cell receptor recognizing the HA-2 minor histocompatibility antigen presented by HLA-A*02:01. The study is intended to evaluate whether administration of TSC-101 following transplantation can improve clinical outcomes compared with standard transplantation alone.

Eligible participants are adults with AML or MDS who are candidates for first allogeneic HCT using a haploidentical or mismatched unrelated donor and post-transplant. Participants assigned to the treatment arm must be HLA-A*02:01 positive, express HA-2, and have a study-eligible HLA-A*02-negative donor. Participants who are HLA-A*02:01 positive but do not have a study-eligible donor, as well as participants who are HLA-A*02:01 negative, may be assigned to the control arm.

Approximately 310 participants will be enrolled, with approximately 155 participants in each study arm. Participants assigned to the treatment arm will receive two infusions of TSC-101 following recovery after transplantation. The first infusion is planned approximately 21 days after HCT (Day +14 to Day +35), and the second infusion is planned approximately 40 days after the first infusion (40 to 68 days after Infusion 1).

All participants will receive SOC transplantation procedures, including one of several protocol-specified RIC regimens followed by peripheral blood stem cell transplantation and post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis.

Safety will be monitored through ongoing review of adverse events, laboratory assessments, and clinical evaluations. An independent Data Safety Monitoring Board (DSMB) will periodically review safety data and study conduct and make recommendations regarding continuation, modification, or termination of the study.

This is an event-driven study. Participants will be followed for up to 3 years after HCT. Participants who receive at least one TSC-101 infusion will subsequently participate in a separate long-term follow-up study for up to 15 years following their final TSC-101 infusion to monitor long-term safety and survival outcomes.

Tipo di studio

Interventistico

Iscrizione (Stimato)

310

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Marlyane Motta
  • Numero di telefono: (857) 399-9887
  • Email: mmotta@tscan.com

Luoghi di studio

  • Stati Uniti
    • Arizona
      • Gilbert, Arizona, Stati Uniti, 85234
        • Non ancora reclutamento
        • Banner Health - MD Anderson Cancer Center
        • Investigatore principale:
          • Yazan Samhouri, MD
      • Scottsdale, Arizona, Stati Uniti, 85258
        • Non ancora reclutamento
        • Honor Health Cancer Transplant Institute
        • Investigatore principale:
          • Abdullah Ladha, MD
    • California
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope
        • Investigatore principale:
          • Monzr M Al Malki, MD
      • Stanford, California, Stati Uniti, 94305
        • Non ancora reclutamento
        • Stanford - School of Medicine
        • Investigatore principale:
          • Hany Elmariah, MD
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • University of Colorado - Anschutz Cancer Center
        • Investigatore principale:
          • Mathew Angelos, MD
      • Denver, Colorado, Stati Uniti, 80218
        • Reclutamento
        • SCRI - Colorado Blood Cancer Institute
        • Investigatore principale:
          • Marcello Rotta, MD
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06510
        • Reclutamento
        • Yale
        • Investigatore principale:
          • Lohith Gowda, MD
    • Florida
      • Hollywood, Florida, Stati Uniti, 33021
        • Reclutamento
        • Memorial Cancer Institute
        • Investigatore principale:
          • Hugo Fernandez, MD
      • Tampa, Florida, Stati Uniti, 33612
        • Reclutamento
        • Moffitt Cancer Institute
        • Investigatore principale:
          • Nelli Bejanyan, MD
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342
        • Reclutamento
        • Northside Hospital
        • Investigatore principale:
          • Melholm Sohl, MD
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60607
        • Non ancora reclutamento
        • University of Chicago
        • Investigatore principale:
          • Gregory Roloff, MD
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • Non ancora reclutamento
        • The University of Kansas Cancer Center
        • Investigatore principale:
          • Rajat Bansal, MD
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Reclutamento
        • Johns Hopkins University
        • Investigatore principale:
          • Tania Jain, MD
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Reclutamento
        • Massachusetts General Hospital
        • Investigatore principale:
          • Yi-Bin Chen, MD
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana-Farber Cancer Institute - Hematology/Oncology
        • Investigatore principale:
          • Mahasweta Gooptu, MD
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48201
        • Reclutamento
        • Karmanos Cancer Institute
        • Investigatore principale:
          • Joseph Uberti, MD
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Reclutamento
        • Hackensack University Medical Center
        • Investigatore principale:
          • Michele Donato, MD
    • New York
      • New York, New York, Stati Uniti, 10029
        • Reclutamento
        • Mount Sinai Hospital
        • Investigatore principale:
          • Alla Keyzner, MD
      • New York, New York, Stati Uniti, 10032
        • Reclutamento
        • Columbia University - Irving Medical Center
        • Investigatore principale:
          • Ran Reshef, MD
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • Reclutamento
        • The University of North Carolina at Chapel Hill
        • Investigatore principale:
          • Anson Snow, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Hospital of the University of Pennsylvania
        • Investigatore principale:
          • Saar Gill, MD, PhD
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • Sarah Cannon Research Institute - TriStar Bone Marrow Transplant (BMT)
        • Investigatore principale:
          • Jeremy Pantin, MD
    • Texas
      • Austin, Texas, Stati Uniti, 76704
        • Reclutamento
        • St. David's South Austin Medical Center
        • Investigatore principale:
          • Uttam Rao, MD
      • Dallas, Texas, Stati Uniti, 75246
        • Reclutamento
        • Baylor University Medical Center
        • Investigatore principale:
          • Luis Pineiro, MD
      • Houston, Texas, Stati Uniti, 76704
        • Reclutamento
        • The University of Texas - MD Anderson Cancer Center
        • Investigatore principale:
          • Uday Popat, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Froedtert & Medical College of Wisconsin
        • Investigatore principale:
          • Sameem Abedin, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Subject Inclusion Criteria:

  1. Patient aged ≥ 18 years at the time of signing informed consent.
  2. Karnofsky Performance Status (KPS) ≥50 at the time of the screening visit.

  3. Undergoing first allo-HCT with a diagnosis of:

    • AML with bone marrow blasts < 5%, absence of circulating blasts, and absence of extramedullary disease.
    • MDS
  4. Must express HLA-A*02:01 as determined by pre-transplant institutional SOC work-up to be eligible for the treatment arm.
  5. Must have the HA-2 positive genotype to be eligible for the treatment arm.

  6. Undergoing RIC HCT using a haplo donor or MMUD.

    • Donors for treatment-arm subjects must be HLA-A*02-negative.
    • Donors for control-arm subjects do not have to be HLA-A*02-negative.
  7. Undergoing use of PTCy for GvHD prophylaxis at standard doses.
  8. Use of peripheral blood stem cell source.
  9. Organ function parameters for transplant eligibility are met per institutional standards. Where organ function may fall outside of institutional standard for transplant, and patient is still proceeding to transplant, the case should be reviewed and approved by the MedicalMonitor.
  10. Patient or legally authorized representative (LAR) capable of giving signed informed consent and willingness to comply with the requirements and restrictions listed in the informed consent form (ICF) and clinical protocol.
  11. Agrees to participate in long-term follow-up (LTFU) for up to 15 years post the final infusion of TSC-101 if they receive a TSC-101 infusion.

  12. Contraceptive use by male and female subjects must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. At a minimum:

    • A male subject must agree to use a highly effective contraceptive during the intervention period and for at least 12 months after the last TSC-101 infusion and refrain from donating sperm during this period.

    • A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

      • Not a woman of childbearing potential (WOCBP) as defined in Appendix 2 OR
      • A WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the intervention period and for at least 12 months after the last TSC-101 infusion.

Subject Exclusion Criteria:

Patients are excluded from the study if any of the following criteria apply:

  1. Potential treatment-arm patient is positive for HLA-A*02:07.

    • Patients considered for the control arm can be positive for HLA-A*02 (including HLA-A*02:07).

  2. For patients with AML: those in third complete remission (CR3) or greater, partial remission, or with active AML disease.
  3. If patient required hemodialysis or mechanical ventilation within 3 months prior to enrollment, circumstances must be discussed with the Sponsor Medical Monitor.
  4. Prior allo-HCT.
  5. Use of anti-thymocyte globulin (ATG), alemtuzumab, or other in vivo or ex vivo T-cell depleting agents from Day -14 (pre-HCT) through end of study (EOS). Corticosteroids and maintenance therapies may be allowed under certain circumstances.
  6. History of hypersensitivity to murine proteins.
  7. Enrollment in a concomitant study with an investigational agent. All other concomitant trials must be reviewed and approved by the Medical Monitor.

  8. Cardiac disease, defined as:

    • Uncontrolled or symptomatic angina within the past 3 months.
    • History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes). Atrial fibrillation with controlled ventricular response on treatment is not an exclusion.
    • Myocardial infarction < 6 months from study entry.
    • Uncontrolled or symptomatic congestive heart failure.
    • Cardiac ejection fraction at rest of less than 40% or shortening fraction of less than 22% by echocardiogram or radionuclide scan (multi-gated acquisition [MUGA] scan).

  9. Medical or psychological conditions that would make the patient an unsuitable candidate for participation on a cell therapy trial, including active central nervous system disease and/or prior malignancy(s) within the last 3 years, except:

    • Lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ will be allowed. Cancer treated with curative intent ≥ 3 years previously will be allowed

Donor Inclusion Criteria:

  1. Male or female ≥ 50 kg and aged ≥ 16 years at the time of signing informed consent who meet the criteria to donate as per the institutional SOC.
  2. Capable of giving signed informed consent, or assent/parental consent per institutional SOC, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  3. For treatment-arm donors: able to undergo peripheral blood stem cell (PBSC) collection and at least 2 rounds of leukapheresis (for both TSC-101 manufacturing and the stem cell collection for HCT).
  4. For treatment-arm donors: negative for all HLA-A*02 alleles • Donors for control-arm subjects do not have to be negative for HLA-A*02 alleles.

Donor Exclusion Criteria:

  1. Donors for control-arm subjects who do not meet institutional standards for donor selection.

  2. Donors for treatment-arm subjects:

    • Who test positive for any of the following: human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2, seropositive or with active hepatitis B or hepatitis C virus infection, syphilis, West Nile virus through central lab testing. Donors who screen positive for Creutzfeldt Jakob disease using donor history questionnaires will also be excluded. Donors with evidence of past cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infections will be allowed.
    • For whom the treating Investigator deems subject level donor-specific HLA antibodies are high enough to warrant treatment with desensitization protocols.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment Arm (TSC-101)
Participants who are HLA-A*02:01-positive and undergoing reduced intensity conditioning hematopoietic stem cell transplantation using allogeneic HLA-A*02 negative donors.
Droga: TSC-101
SOC + TSC-101
Comparatore attivo: Control Arm (Standard of Care)
  1. Participants who are not HLA-A*02:01-positive, HA-2-positive, or who are treatment-arm eligible but for whom an HLA-A*02-negative donor cannot be identified, will be assigned to the control arm and receive allo-HCT alone.
  2. Participants who are HLA-A*02:01 negative, will be assigned to the control arm and receive allo-HCT alone.
Altro: Controllo
SOC da solo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Relapse-free survival (RFS)
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 by assessing relapse-free survival (RFS)
3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Event-free survival (EFS)
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 by event-free survival (EFS)
3 years
Overall survival (OS)
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 by overall survival (OS)
3 years
Time to relapse (TTR)
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 by assessing time to relapse (TTR)
3 years
Changes over time in Quality of Life Score - EQ-5D-5L
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of EQ-5D-5L
3 years
Changes over time in Quality of Life Score - FACT-Leu
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of FACT-Leu
3 years
Changes over Quality of Life Scores in FACT-BMT
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of FACT-BMT
3 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence and severity of treatment-emergent adverse events
Lasso di tempo: 3 years
To determine the safety and tolerability of TSC-101 through incidence and severity of treatment-emergent adverse events
3 years
TSC-101 Expansion and Persistence
Lasso di tempo: 3 years
To characterize the in vivo cellular pharmacokinetic (PK) profile of TSC-101 by analysis of peak persistence and other relevant PK parameters of TSC-101cells
3 years
Non-Relapse Mortality
Lasso di tempo: 3 years
Assess non-relapse mortality (NRM) of TSC-101
3 years
Overall Response Rates
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 retreatment infusion through: overall response rates assessed by the Investigator.
3 years
MRD-negative CR in bone marrow
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 retreatment infusion though analysis of the proportion of subjects achieving MRD-negative CR in bone marrow
3 years
Full Donor Chimerism
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 retreatment infusion by analyzing the proportion of subjects achieving full donor chimerism.
3 years
Duration of response (DoR)
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 retreatment infusion by Duration of response (DoR)
3 years
EFS post-retreatment
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 retreatment infusion by EFS post-retreatment
3 years
OS post-retreatment
Lasso di tempo: 3 years
To determine the efficacy of TSC-101 retreatment infusion by OS post-retreatment
3 years
MRD positivity
Lasso di tempo: 3 years
To determine presence of and changes in minimal residual disease (MRD) by rates of MRD positivity pre-and post-HCT
3 years
Post-HCT conversion of MRD
Lasso di tempo: 3 years
To determine presence of and changes in minimal residual disease (MRD) by proportion of subjects with post-HCT conversion of MRD.
3 years
Changes in Donor Chimerism
Lasso di tempo: 3 years
To determine presence and changes of mixed chimerism and association with relapses by analyzing changes in donor chimerism over time.
3 years
Predictive Value of Donor Chimerism
Lasso di tempo: 3 years
To determine presence and changes of mixed chimerism and association with relapses through predictive value of mixed or full donor chimerism for relapse.
3 years
Healthcare Utilization post-HCT
Lasso di tempo: 1 year
To determine the healthcare utilization post-HCT by hospitalization days through one-year post-HCT.
1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

TScan Therapeutics, Inc.

Investigatori

  • Direttore dello studio: Shrikanta Chattopadhyay, MD, TScan Therapeutics

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 giugno 2026

Completamento primario (Stimato)

1 giugno 2029

Completamento dello studio (Stimato)

1 giugno 2029

Date di iscrizione allo studio

Primo inviato

1 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 luglio 2026

Primo Inserito (Effettivo)

14 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • TSCAN-001 (Phase 3)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi